Keensight Capital Acquires Majority Stake in Axxam

Keensight Capital Agrees to Acquire Quanos Solutions from IK Partners

December 20, 2022

Software

Keensight Capital has signed an agreement to acquire Quanos Solutions GmbH from IK Partners' IK Small Cap II Fund. Quanos, headquartered in Nuremberg, Germany, is a provider of industrial aftersales and digital technical documentation software (around 270 employees and 1,000+ customers); Keensight will support the company’s next phase of growth, expanding its product suite, market penetration and international reach. Financial terms were not disclosed and the deal is subject to customary approvals.

Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare

May 25, 2021

Healthcare Services

Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.

Keensight Capital Invests in CatSci Ltd

January 15, 2022

Healthcare Services

Keensight Capital has made a growth investment in CatSci Ltd, a Cardiff‑headquartered Contract Research Organisation (CRO) formed as a 2010 spin‑out from AstraZeneca. Keensight will invest alongside CatSci founders, senior management and employees to support the company's continued growth and capability expansion in small‑molecule and oligonucleotide CMC development and scale‑up.

Keensight Capital Acquires Inke from Neuraxpharm

May 1, 2023

Pharmaceuticals

Keensight Capital has signed a binding agreement to acquire Inke, a Spain-based specialist developer and manufacturer of inhalation active pharmaceutical ingredients (APIs), from Neuraxpharm Group; financial terms were not disclosed and the deal is expected to close in May 2023. Neuraxpharm divested Inke to sharpen its focus on CNS therapies, while Keensight will support Inke's management team to expand its footprint, broaden its offering and grow its product portfolio.

Keensight Capital Acquires Majority Stake in Biovian

May 23, 2018

Biotechnology

Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.

Keensight Capital Acquires Majority Stake in ACTICO Group from Bregal Unternehmerkapital Funds

March 13, 2025

Software

Keensight Capital has signed an agreement to acquire a majority stake in ACTICO Group, a Germany-headquartered provider of regulatory compliance, decision automation, and credit risk management software. Existing shareholder Bregal Unternehmerkapital Funds will partially exit and reinvest alongside Keensight; Keensight plans to support ACTICO's international expansion and product roadmap, with the deal expected to close in May 2025 subject to regulatory approvals.